HI SB49 | 2025 | Regular Session
Status
Spectrum: Slight Partisan Bill (Democrat 2-1)
Status: Introduced on January 15 2025 - 25% progression
Action: 2025-01-29 - The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 5 Aye(s): Senator(s) San Buenaventura, Aquino, Hashimoto, Keohokalole, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none.
Text: Latest bill text (Introduced) [HTML]
Status: Introduced on January 15 2025 - 25% progression
Action: 2025-01-29 - The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 5 Aye(s): Senator(s) San Buenaventura, Aquino, Hashimoto, Keohokalole, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none.
Text: Latest bill text (Introduced) [HTML]
Summary
Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions. Effective 1/1/2026.
Title
Relating To Terminal Illnesses.
Sponsors
Roll Calls
2025-01-29 - Senate - Senate Health and Human Services: Passed, With Amendments (Y: 5 N: 0 NV: 0 Abs: 0) [PASS]
History
| Date | Chamber | Action |
|---|---|---|
| 2025-01-29 | Senate | The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 5 Aye(s): Senator(s) San Buenaventura, Aquino, Hashimoto, Keohokalole, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none. |
| 2025-01-24 | Senate | The committee(s) on HHS has scheduled a public hearing on 01-29-25 1:00PM; Conference Room 225 & Videoconference. |
| 2025-01-16 | Senate | Referred to HHS, CPN/JDC. |
| 2025-01-15 | Senate | Introduced and passed First Reading. |
| 2025-01-08 | Senate | Pending Introduction. |
